FindMyKOL
Clinical trialNCT07072234RecruitingPhase 1Interventional

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

SponsorM.D. Anderson Cancer CenterEnrollment30Clear Cell CarcinomaGrowth FactorPhase 1
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Andrew C Johns, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CyclophosphamateDexamethasone →Fludarabine →Lymphodepleting chemotherapyTGFBR-2 KO CD70 CAR NK
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Sept 2025
Primary completion
1 Feb 2028
Completion
1 Feb 2030
Last update posted
29 Apr 2026
Registered enrollment
30
Registry id
NCT07072234
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.